Rachel D Slack

US Patent:

20130157987, Jun 20, 2013

Filed:

Jan 13, 2011

Appl. No.:

13/521980

Inventors:

Gary H. Posner - Baltimore MD, US
Lindsey C. Hess - Pflugerville TX, US
Alvin S. Kalinda - Bloomington IN, US
Rachel D. Slack - Baltimore MD, US
Uttam Saha - Thornhill, CA
P. Martin Petkovich - Kingston, CA

Assignee:

JOHNS HOPKINS UNIVERSITY - Baltimore MD
CYTOCHROMA INC. - Markham ON

International Classification:

A61K 45/06
A61K 31/593
C07C 401/00

US Classification:

514167, 552653

Abstract:

This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

US Patent:

20210400977, Dec 30, 2021

Filed:

Nov 15, 2019

Appl. No.:

17/296742

Inventors:

- Philadelphia PA, US
Rachel SLACK - Bel Air MD, US
Andrew Jon DEANGELIS - Garnet Valley PA, US

International Classification:

A01N 53/00
C07C 233/62
A01N 25/02
A01P 15/00

Abstract:

Disclosed are compounds of Formula 1, N-oxides, and salts thereof,

US Patent:

20210024523, Jan 28, 2021

Filed:

Nov 12, 2018

Appl. No.:

16/762998

Inventors:

- Bethesda MD, US
JoLynn Barbara GIANCOLA - Boardman OH, US
Rachel D. SLACK - Baltimore MD, US

International Classification:

C07D 471/10
C07D 211/58
C07D 241/04

Abstract:

Disclosed herein are a series of modafinil analogue compounds that bind with moderate to high affinity to the dopamine (DA) transporter (DAT) and several analogues also having affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. Employing aminopiperidine, piperidineamino, spirobicyclodiaza, or substituted piperazine functional groups, desired dopamine transporter affinity has been retained along with improved metabolic stability over unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment.

US Patent:

20190060456, Feb 28, 2019

Filed:

Oct 25, 2018

Appl. No.:

16/170487

Inventors:

- Baltimore MD, US
- Grand Cayman, KY
Alvin S. Kalinda - Bloomington IN, US
Rachel D. Slack - Baltimore MD, US
Uttam Saha - Thornhill, CA
P. Martin Petkovich - Kingston, CA

International Classification:

A61K 45/06
C07C 401/00
A61K 31/593

Abstract:

This present disclosure is directed to novel prodrugs of activated vitamin Dcompounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

US Patent:

20180117156, May 3, 2018

Filed:

Oct 2, 2017

Appl. No.:

15/722694

Inventors:

- Baltimore MD, US
Alvin S. Kalinda - Bloomington IN, US
Rachel D. Slack - Baltimore MD, US
Uttam Saha - Thornhill, CA
P. Martin Petkovich - Kingston, CA

International Classification:

A61K 45/06
C07C 401/00
A61K 31/593

Abstract:

This present disclosure is directed to novel prodrugs of activated vitamin Dcompounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.

US Patent:

20150183798, Jul 2, 2015

Filed:

Apr 16, 2012

Appl. No.:

14/111991

Inventors:

Gary H. Posner - Baltimore MD, US
Rachel D. Slack - Baltimore MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

C07D 493/18
A61K 45/06
A61K 31/357

Abstract:

Anilide derivatives of the natural trioxane artemisinin were prepared and evaluated for antimalarial efficacy in -infected mice. Selected anilides derivatives administered orally as one single-digit dose combined with mefloquine hydrochloride were completely curative, i.e., all 5 of the mice in the particular treatment group had no detectable parasitemia on day 30 post infection, gained as much weight by day 30 post infection as the control mice (no infection), and behaved normally.

US Patent:

20150031677, Jan 29, 2015

Filed:

Feb 28, 2013

Appl. No.:

14/381494

Inventors:

- BALTIMORE MD, US
Alexander M. Jacobine - Baltimore MD, US
Rachel D. Slack - Baltimore MD, US
Jennifer R. Mazzone - Baltimore MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - BALTIMORE MD

International Classification:

C07D 493/22
A61K 31/4192
A61K 45/06
A61K 31/357

US Classification:

51421113, 549354, 514450, 548260, 514359, 514313, 514305, 514314, 514311, 5142262, 514327, 5142258, 5142255, 51426622, 514220, 51425404, 51425307

Abstract:

Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.